Member Info for RorkesDrift

Wyn has a point. Share price movements can happen quickly particularly in companies as leaky as Avacta and before the majority of PIs know why - the placing is an example - indeed someone named the exact price before the RNS.

However, at the moment £1.30 seems to be the balance point and it moves around this. PL75 is only making the point that it is the nature of the beast for it to do that but we should treat them both the same. If you have done your own research, spread your scanning beyond Avacta and take proven pump and dumpers with a pinch of salt then risks and emotions should be lower.

We are back to the RNS will sort this out one way or the other. If other companies don't mention LFD I'm not worrying

Well given I haven't mentioned clinical validity it seems odd you have gone down that route. You suggested that there were 20 patients per day available for trusting - I merely pointed out that they could be in 20 different hospitals.

For self tests I'd create an assessment involving users trying out the test and then completing a questionnaire to give me both qualitative feedback andvquantative (could call tgisva user ability index if comparing). Well that's what I did in the seven clinical trials I ran and published - you might have read them whilst you did the paperwork in regulatory.

Timeline?

Oh dear. Clip clop, clip clop - make it up as you go along, clip clop, adopt patroninising sneer and self delusion, clip clop, clip clop disappear into sunset on a donkey

The 20 patients Orphidian mentions though would be scattered across the different hospitals in the UK so not as easy as implied - I suspect they will want to reduce the number of centers testing for consistency.

This is also intended to be a at home test so you would want to test that aspect including ease of use and instructions.

Apologies to everyone else.

Chengdo - have a look at your post on other board.

Is the interim analysis going to be statistical or qualitative. I understand the trial is on going hence the term interim.

Thevaim is to inform the covid result - that could be a simple there are no data that counteract that result. Fine balance. Just hope that COPD trial was overpowered on primary efficacy variable

Its not so much that I want it but bit wants me. Let's call it an investment and we get 20 of us to do a timeshare.

Admittedly I was looking at it on-line

https://www.silverstoneauctions.com/events/2020-auctions/the-silverstone-classic-live-online-auction-2020/the-silverstone-classic-live-online-auction-2020/friday-31st-july-sale-11am-bst/1995-sunseeker-tomahawk-41-13m-formerly-the-property-of-sir-roger-moore-kbe

I was having a look at Roger Moore's the other day. Honest.

I'm afraid I don't agree that the other drugs are falling over. Some have but not all. Drugs that have been shown to offer benefit are dexamethasone and remdesiver.

Drugs that look like they will work are convalescent plasma (not a drug) and IFN-B.

Drugs to be reporting soon include IL1 receptor antagonists

Needs a technician, takes 90 minutes, expensive and not enough of them.

But apart from that...

I'm presuming the weatherby whaler will be doing the eat out to help out thing. I'm going.

Not a stalker but...

At the risk of being in the middle the time frames for development are relatively quick. However, the tone until now has been that we are already there - the biotech investors know the score but difficult for others to watch other drugs making an impact (and revenue) now whilst disease is at bits peak.

That said the anti CD3 is more advanced and the acceleration on IL6 product will bring the original planned revenue dates forward even without covid.

So good news but patience required - I'm not relying on robin hood since that would me joining them. Look at seven day moving average of share price is more relaxing.

GLA

Bump

I'm with degiro and takes two days to clear funds

We know how leeky avacta is. That said a test fail doesn't take long to put out and the city fatcats dont need to be involved.

Many of you youngsters won't remember the great crash. The share price went down from £2.15 to about £1. I'm proud to say "I was there". This Avacta ride is a bit of a roller coaster but you either believe your own research or you don't.

Worse that happens is I wait first the cancer drug results.

Its a risk and I'm taking it - yeeeeeeeeee hah

I think his point is his exit will also be 20% lower. Pointing out how much the share will go up is making it worse which would wind anyone up

Oh hang on....

I recall something about Imperial working on something but not for awhile.

I am starting to get excited - step away from the only break glass in case of emergency funds

Also google breathnomics

Also Google it with university of leicester

Sorry to rush off